AbbVie Projects Strong 2026 Growth as Skyrizi and Rinvoq Replace Humira

AbbVie projects adjusted diluted earnings per share of $14.37 to $14.57 in 2026, representing a 43% to 45% increase from 2025, as the company executes its strategy to replace revenue lost from Humira's patent expiration. The company anticipates 9.5% sales growth by 2026, driven primarily by newer immunology drugs and an expanding oncology portfolio.

Fourth-quarter revenue rose 10% year-over-year to $16.6 billion. Sales of immunology drugs Skyrizi and Rinvoq continue to grow, with the two drugs on track to surpass Humira's peak annual sales combined in 2025. The company projects combined sales of over $31 billion for Skyrizi and Rinvoq by 2026. Humira's sales are declining due to biosimilar competition following its 2023 patent loss.

Oncology drugs Elahere and Venclexta continue gaining ground, while migraine treatments Qulipta and Ubrelvy are building strong market momentum. AbbVie boasts approximately 90 clinical development programs spanning immunology, oncology, neuroscience, and metabolics.

AbbVie recently raised its dividend by 5% to $1.73 per share, marking the 13th consecutive year of increases. The company has increased its dividend for 54 consecutive years, earning the title of Dividend King. The dividend yield significantly exceeds the S&P 500 average.

The company's product portfolio includes immunology, oncology, aesthetics, neuroscience, eye care, and other key products. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care products. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.

Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder. The company is headquartered in Illinois.

AbbVie stock rose 24% during the 2022 bear market, demonstrating resilience during economic slowdowns. A survey by Natixis Investment Managers reveals that 74% of institutional money managers anticipate a market correction in 2026, citing concerns over the tech bubble, geopolitics, and macroeconomic factors. Wall Street analysts maintain a moderate buy rating on the stock, with 12 buy ratings and 6 hold ratings.